Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology is under clinical development by ImmunityBio and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology overview
Monoclonal antibody conjugate is under development for the treatment of end-stage non-small cell lung cancer and mesothelioma. The drug candidate constitutes immune adjuvant EDV nanocells filled with a payload of siRNA and PNU-682. These payload-packaged EDVs are coated with a bispecific antibody which targets EGFR. siRNA targets polo like kinase (PLK1). It is developed based on a bacterially-derived EDV nanocell platform.
It was also under development for treatment of multiple cancer indications
ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.
For a complete picture of Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology’s drug-specific PTSR and LoA scores, buy the report here.